11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyJuha O. Rinne, Michael Grundman, David J. Brooks et al.|The Lancet Neurology|2010Cited by 696
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysisReisa A. Sperling, Michael Grundman, Murray A. Raskind et al.|The Lancet Neurology|2012Cited by 512
Amyloid-β <sup>11</sup> C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trialsEnchi Liu, Arthur Spirling, Mark E. Schmidt et al.|Neurology|2015Cited by 152